Acute myeloid leukaemia (AML) is a deadly disease with few treatment options compared to many other cancers. We have tested a molecule, the RAC-inhibitor EHop-016, which inhibits migration of cancer cells. We tested the effect of this molecule on AML cells transplanted into zebrafish larvae, and found that the cells did not migrate to the haematopoietic tissue. More importantly, we found that treatment with EHop-016 together with the commonly used AML drug daunorubicin was better that either drug alone, and could be a way to overcome therapy resistance. These findings were recently published in the journal Translational Oncology.